Eli Lilly Announces Acquisition of Kelonia Therapeutics for Up to $7 Billion

1-Minute Brief

The acquisition expands Eli Lilly's presence in cancer treatment by adding Kelonia's in vivo CAR-T cell therapy technology.

Key Facts

• Eli Lilly is acquiring Kelonia Therapeutics in a deal valued at up to $7 billion.
• Kelonia is developing technology to reprogram patients' T-cells inside the body to target cancer.
• The acquisition is part of Lilly's ongoing investment in Massachusetts-based biotech firms.
• Kelonia specializes in in vivo CAR-T cell therapies, which aim to treat cancer by modifying immune cells within the patient.
• Reports of the deal's value have varied, with some sources citing figures between $2 billion and $7 billion.

What Happened

Eli Lilly announced it will acquire Kelonia Therapeutics, a Boston-area biotech company focused on in vivo CAR-T cell therapies, in a deal that could be worth up to $7 billion.

Why It Matters

This move signals Eli Lilly's continued investment in advanced cancer therapies and may accelerate the development of treatments that use patients' own immune systems to fight cancer. Reports vary on the total value of the deal, with some sources citing $2 billion and others up to $7 billion.

What's Next

The completion of the acquisition is expected to integrate Kelonia's technology into Lilly's oncology pipeline. Further updates on regulatory approval and integration plans are anticipated.